ReviewMolecular biology reports2026
Natural extracts for the treatment of atherosclerosis.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is a cardiovascular disease with high mortality and disability rates, and the increasing number of cases urgently demands more effective therapeutic options. AS is characterized by complex pathogenesis and multiple complications, where single-drug therapy has limited efficacy and combination therapy increases safety risks. Natural extracts (NEs) offer advantages such as multi-target, multi-pathway effects and low side effects, showing significant potential in AS prevention and adjunctive treatment. This article systematically reviews existing studies and analyzes the advantages and limitations of NEs in cardiovascular disease management. The development of novel formulations using modern biotechnology and drug delivery systems holds promise for better AS treatment. Although challenges remain in bioavailability and pharmacokinetics, ongoing advances in extraction techniques, delivery systems, and nanotechnology warrant further research into NEs for AS therapy.
Indexed as
Identifiers
42363943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.